195 related articles for article (PubMed ID: 22035385)
1. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
2. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
3. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
4. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
6. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
7. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
9. A case report and discussion of cetuximab-induced folliculitis.
Adams DH; Nutt T
Am J Clin Dermatol; 2006; 7(5):333-6. PubMed ID: 17007545
[TBL] [Abstract][Full Text] [Related]
10. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
11. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
Duvic M
Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
[TBL] [Abstract][Full Text] [Related]
14. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
Cholongitas E; Pipili C; Ioannidou D
J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
16. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
17. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
18. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
19. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
[TBL] [Abstract][Full Text] [Related]
20. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]